Key facts
- Magnitude Biosciences’s last known valuation is $3.6M (Mar 2025).
- It has raised $2.9M; the latest was Later Stage VC ($900K) in Mar 2025.
- Notable investors include Innovate UK, Maven Capital Partners UK, Government of UK, Northstar Ventures, Business Durham — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Magnitude Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Magnitude Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Magnitude Biosciences
Operator of a patented in vivo testing platform designed to accelerate drug and product development through rapid, cost-effective data generation using C. elegans. The company offers high-throughput, whole-organism insights into efficacy, toxicity, and mechanisms of action, enabling pharmaceutical, biotech, and nutraceutical developers to reduce preclinical timelines and costs with an ethical alternative to mammalian models.
- Sector
- Healthcare
- HQ
- Sedgefield, United Kingdom
- Founded
- 2018
- Employees
- 19
- Website
- magnitudebiosciences.com/
- Ownership
- Privately Held (backing)
Magnitude Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Magnitude Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Magnitude Biosciences in its N-PORT filings yet. We sweep new filings monthly.